Federated Hermes Inc. Sells 96,345 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Federated Hermes Inc. lowered its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 9.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 936,107 shares of the company’s stock after selling 96,345 shares during the period. Federated Hermes Inc.’s holdings in Hims & Hers Health were worth $8,331,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Hims & Hers Health by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after acquiring an additional 1,561 shares during the period. Pathstone Family Office LLC increased its stake in Hims & Hers Health by 2.8% during the 3rd quarter. Pathstone Family Office LLC now owns 65,876 shares of the company’s stock worth $414,000 after acquiring an additional 1,824 shares during the period. Baldwin Brothers LLC MA increased its stake in Hims & Hers Health by 17.0% during the 4th quarter. Baldwin Brothers LLC MA now owns 22,128 shares of the company’s stock worth $197,000 after acquiring an additional 3,215 shares during the period. Arizona State Retirement System increased its stake in Hims & Hers Health by 9.6% during the 3rd quarter. Arizona State Retirement System now owns 40,050 shares of the company’s stock worth $252,000 after acquiring an additional 3,520 shares during the period. Finally, Teacher Retirement System of Texas increased its stake in Hims & Hers Health by 7.4% during the 3rd quarter. Teacher Retirement System of Texas now owns 72,253 shares of the company’s stock worth $454,000 after acquiring an additional 4,954 shares during the period. Institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 15,100 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $9.01, for a total transaction of $136,051.00. Following the completion of the transaction, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at approximately $465,393.53. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Soleil Boughton sold 4,080 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the completion of the transaction, the insider now directly owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 15,100 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $9.01, for a total value of $136,051.00. Following the transaction, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at $465,393.53. The disclosure for this sale can be found here. Insiders sold a total of 548,150 shares of company stock valued at $7,327,717 in the last three months. Insiders own 31.63% of the company’s stock.

Hims & Hers Health Price Performance

NYSE HIMS opened at $12.34 on Thursday. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $17.16. The business’s fifty day moving average is $13.65 and its 200 day moving average is $9.99.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. During the same quarter last year, the business posted ($0.05) EPS. Hims & Hers Health’s revenue for the quarter was up 47.4% on a year-over-year basis. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.1 EPS for the current year.

Analysts Set New Price Targets

HIMS has been the topic of a number of recent research reports. Tigress Financial raised their price objective on Hims & Hers Health from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 5th. Guggenheim raised their target price on Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Citigroup raised their target price on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Truist Financial raised their target price on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a report on Tuesday, February 27th. Finally, Canaccord Genuity Group assumed coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $14.85.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.